Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas

Hans K. Ghayee, Alessio Giubellino, Arielle Click, Payal Kapur, Alana Christie, Xian Jin Xie, Victoria Martucci, Jerry W. Shay, Rhonda F. Souza, Karel Pacak

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Background: Pheochromocytomas (PCCs)/paragangliomas (PGLs) are neuroendocrine tumours that may cause arrhythmia and death if untreated. Treatment for patients with metastatic tumours is lacking. As new PCC/PGL susceptibility genes are discovered that are associated with the mTOR pathway, treatment targets focusing on this pathway are being intensively explored. Design: Twenty-one human PCC/PGLs were analysed from two tertiary care centres. Immunohistochemistry (IHC) analysis was performed for phospho-mTOR (pmTOR), phospho-S6K (pS6K), phosphoinositide 3-kinase (PI3K), phospho-4EBP1 (p4EBP1), HIF1α and MIB-1 in 6 metastatic SDHB PCC/PGLs, 15 nonmetastatic PCC/PGLs, (including 1 TMEM127 PCC and 1 nonmetastatic SDHB PGL) and 6 normal adrenal medullas. The product of the intensity of stain and percentage of cells stained was calculated as an H score. Results: Using a two-sample t-test and paired t-test, pmTOR and pS6K had significantly higher H scores in nonmetastatic PCC/PGLs than in metastatic SDHB PCC/PGLs. HIF1α had significantly higher H scores in metastatic SDHB PCC/PGLs compared with nonmetastatic PCC/PGLs and normal adrenal medulla. No difference in H scores was seen with p4EBP1, PI3K and MIB-1 when comparing metastatic SDHB PCC/PGLs and nonmetastatic PCC/PGLs. Significantly higher difference in pS6K was seen in normal adrenal medullas compared to nonmetastatic PCC/PGLs and metastatic SDHB PCC/PGLs. Conclusion: The present results suggest that the use of mTOR inhibitors alone for metastatic SDHB PCC/PGLs may not achieve good therapeutic efficacy in patients.

Original languageEnglish (US)
Pages (from-to)970-977
Number of pages8
JournalEuropean Journal of Clinical Investigation
Volume43
Issue number9
DOIs
StatePublished - Sep 1 2013

Keywords

  • Paraganglioma
  • PmTOR
  • SDHB

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas'. Together they form a unique fingerprint.

  • Cite this

    Ghayee, H. K., Giubellino, A., Click, A., Kapur, P., Christie, A., Xie, X. J., Martucci, V., Shay, J. W., Souza, R. F., & Pacak, K. (2013). Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas. European Journal of Clinical Investigation, 43(9), 970-977. https://doi.org/10.1111/eci.12127